This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

28 Oct 2016

BMS's Yervoy awarded Prix Galien USA Discovery of the Decade

Award recognizes BMS for driving innovation in immuno-oncology.

Bristol-Myers Squibb (BMS) has received the Prix Galien USA Discovery of the Decade biotech award for Yervoy (ipilimumab), the company’s recombinant, human monoclonal antibody. In honour of the 10th anniversary of the Prix Galien awards and recognizing this decade as one of history's most productive for research, this special honour distinguishes BMS for its innovative discovery and development of Yervoy, which is now approved in more than 50 countries for treatment of unresectable or metastatic melanoma. The award is also a testament to BMS’s efforts to establish immuno-oncology as a transformational approach to treating a wide range of malignancies.

“We are honored to receive this special recognition for Yervoy, an agent that ushered in what can easily be described as a historical time in cancer research,” said Francis Cuss, chief scientific officer and executive vice president, Research & Development, BMS. “We are extremely proud that the highly distinguished selection committee recognized the extraordinary vision of our scientists and the strength of our research and development program, which includes a robust portfolio of early assets both in immuno-oncology and in targeted therapies.”

Related News